EGFR and lung adenocarcinoma: However, in the modern era of targeted therapy, clinicians have the option of treating lung adenocarcinoma patients harboring EGFR mutations with EGFR tyrosine kinase inhibitors (TKIs), which have improved the survival of such patients.